Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 4 · newest first

  1. The Link between Modifiable Risk Factors and Myeloid Disorders—From Plate to PathogenesisBlood Cancer Discovery · 2025
  2. PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic LeukemiaBlood Cancer Discovery · 2025
  3. Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic DependencyBlood Cancer Discovery · 2025
  4. Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell LymphomaBlood Cancer Discovery · 2025
  5. CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma ModelsBlood Cancer Discovery · 2025
  6. A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell LymphomaBlood Cancer Discovery · 2025
  7. Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCLBlood Cancer Discovery · 2025
  8. ID2 suppresses multiple myeloma cell proliferation by repressing the activity of the transcription factor TCF3Blood Cancer Discovery · 2025
  9. Acquired and Selected: Tracking Antigen Escape during T Cell–Redirecting Therapies in Multiple MyelomaBlood Cancer Discovery · 2025
  10. The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World PracticeBlood Cancer Discovery · 2025
  11. Perspectives on Newly Diagnosed Myeloma Treatment and Emerging ChallengesBlood Cancer Discovery · 2025
  12. Combination Strategies with Menin Inhibitors for Acute LeukemiaBlood Cancer Discovery · 2025
  13. Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapiesBlood Cancer Discovery · 2025
  14. Identification of a CD138-negative therapy-resistant subpopulation in multiple myeloma with vulnerability to splicing factor inhibitionBlood Cancer Discovery · 2025
  15. IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular LymphomaBlood Cancer Discovery · 2025
  16. Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in MyelomaBlood Cancer Discovery · 2025
  17. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy ConsortiumBlood Cancer Discovery · 2025
  18. An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and ChemoresistanceBlood Cancer Discovery · 2025
  19. Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesBlood Cancer Discovery · 2025
  20. DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell ResponseBlood Cancer Discovery · 2025
  21. The Silence of the Lambdas: Hidden Complexities in the Evolution of Double-Hit LymphomasBlood Cancer Discovery · 2025
  22. Clinical Significance of TP53 -Mutant Clonal Hematopoiesis Across DiseasesBlood Cancer Discovery · 2025
  23. Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2025
  24. Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic MalignanciesBlood Cancer Discovery · 2025
  25. B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 RearrangementsBlood Cancer Discovery · 2025
  26. Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN StudyBlood Cancer Discovery · 2025
  27. DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical FeaturesBlood Cancer Discovery · 2025
  28. Single-cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML DifferentiationBlood Cancer Discovery · 2025
  29. Single-cell Resolved Oncogene Co-expression: From Principles to Clinical ImpactBlood Cancer Discovery · 2025
  30. Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination StrategiesBlood Cancer Discovery · 2025
  31. Q&A: Louis Staudt on Molecular Classification of CancerBlood Cancer Discovery · 2025
  32. The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell TherapyBlood Cancer Discovery · 2025
  33. Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination TherapyBlood Cancer Discovery · 2025
  34. Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple MyelomaBlood Cancer Discovery · 2025
  35. Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7qBlood Cancer Discovery · 2025
  36. Immune Escape of Acute Myeloid Leukemia after TransplantationBlood Cancer Discovery · 2025
  37. Selective Enhancer Dependencies in MYC -Intact and MYC -Rearranged Germinal Center B-cell Diffuse Large B-cell LymphomaBlood Cancer Discovery · 2025
  38. A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for LymphomaBlood Cancer Discovery · 2025
  39. SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell–Mediated CytotoxicityBlood Cancer Discovery · 2025
  40. High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II StudyBlood Cancer Discovery · 2025
  41. Addressing Health Disparities in Hematologic Malignancies: from Genes to OutreachBlood Cancer Discovery · 2025
  42. Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell TransplantationBlood Cancer Discovery · 2025
  43. Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell LymphomaBlood Cancer Discovery · 2024
  44. The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia DevelopmentBlood Cancer Discovery · 2024
  45. Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A RoadmapBlood Cancer Discovery · 2024
  46. CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T CellsBlood Cancer Discovery · 2024
  47. Venetoclax-Based Combination Regimens in Acute Myeloid LeukemiaBlood Cancer Discovery · 2024
  48. Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaBlood Cancer Discovery · 2024
  49. Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant MicroenvironmentBlood Cancer Discovery · 2024
  50. A View of Myeloid Transformation through the Hallmarks of CancerBlood Cancer Discovery · 2024